Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
about
Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysisIncidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysisIntra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.
P2860
Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Bevacizumab increases the risk ...... randomized controlled trials.
@en
type
label
Bevacizumab increases the risk ...... randomized controlled trials.
@en
prefLabel
Bevacizumab increases the risk ...... randomized controlled trials.
@en
P2093
P1476
Bevacizumab increases the risk ...... randomized controlled trials.
@en
P2093
Qing Zhang
Wei-Xiang Qi
Xiao-Mao Guo
P304
P356
10.1016/J.CRITREVONC.2015.02.007
P577
2015-02-19T00:00:00Z